¤K¤Q¤C¦~¤º¬ì±M¬ìÂå®v¦Ò¸Õµ§¸ÕÃD -- ¸~½F¬ì

(E) 1. ³\¦h¤Æ¾ÇªvÀøÃĪ«¤§§@¥Î¾÷Âà¡A¬O°w¹ï²Ó­M¤º¬Y¨Ç¯S©w»Ã¯À©Î³J¥Õ½è²£¥Í§í¨î©Î¯}Ãa¡C¤U¦C°t¹ï¦óªÌ¿ù»~¡H
A.Fluorouracil : thymidylate synthetase
B.Methotrexate : dihydrofolate reductase
C.Paclitaxel : microtubule
D.Etoposide : topoisomerase II
E.Vincristine : DNA polymerase
 
(D) 2. Ãö©óªÍÀùªº±Ô­z¡A¤U¦C¦óªÌ¿ù»~¡H
A.¤£½×¬O«D¤p²Ó­MÀù¡]non-small cell lung cancer¡^©Î¬O¤p²Ó­MÀù¡]small cell lung cancer¡^§¡¥H§lµÒ¬°³Ì­«­n¤§­PÀù¦]¤l
B.¸û±`¨£©ó¤p²Ó­MªÍÀùªº²§±`²üº¸»X¤Àªc¥]¬AACTH¡]adrenocorticotropin¡^¡AADH¡]antidiuretic hormone¡^µ¥
C.«D¤p²Ó­MªÍÀù©Ò¤Þ°_¤§°ª¦å¶t¯g¡A¤j¦h»P¸~½F©Ò¤Àªc¤§¡u°Æ¥Òª¬¸¢¿E¯À¬ÛÃöúTÐ`¡v¡]parathyroid hormone-related peptide, PTH-rP¡^¦³Ãö
D.«D¤p²Ó­MªÍÀù²£¥Í´c©Ê¦Ø½¤¿n¤ô¡]malignant pleural effusion¡^®É¤´¥i¥H¥~¬ì¤â³Nªv¡
E.¤p²Ó­MªÍÀù¦X¨Ö¤WµÄÀR¯ß¯g­Ô¸s¡]superior vena cava syndrome¡^¥iÀu¥ý¦Ò¼{¤Æ¾ÇªvÀø
 
(C) 3. 70·³¨k©Ê¦]¬°¬ðµM¤U¥b¨­ÅõºÈ¡]paraplegia¡^¨Ó«æ¶E´NÂå¡C¯f¤H¹L¥hµL­«¤j¯f¥v¡Aµo¯f«e¤@­Ó¤ë°_¦³¤U­Iµh¯gª¬¡CX¥úÀˬdµo²{²Ä¤@¸y´Õ²£¥Í¯f²z©Ê°©§é¡]pathological fracture¡^¡A¨Ã²£¥Í¯áÅèÀ£­¢¡]spinal cord compression¡^¡C¦å²GÀˬdalkaline phosphatase 780 U/L, calcium 3.8 mmol/L¡C¤U¦C¦óªÌ¿ù»~¡H
A.Âಾ©ÊÀù¯g¤Þ°_¤§¯áÅèÀ£­¢¡A¥i¨Ï¥Î¤j¾¯¶qÃþ©T¾J¤Î©ñ®g½uªvÀø¡C
B.·U¦­¶}©l¶i¦æªvÀø¡A«h¤é«á¯f±w¤§¯«¸g¾Ç¯gª¬¯à§ïµ½ªº¾÷·|¤]·U¤j¡C
C.°ª¦å¶t¯g¡]hypercalcemia¡^¤§ªvÀø¡A¥]¬A­­¨î¤ô¥÷Äá¨ú¡B¨Ï¥Î§Q§¿¾¯¤ÎbisphosphonateÃþÃĪ«¡C
D.¸~½F«ü¼Ð¦pCEA ( carcinoembryonic antigen¡^¡A PSA¡]prostate specific antigen¡^¥i¥HÀ°§UŲ§O¶EÂ_¡C
E.­Y²Õ´¶EÂ_Ãҹꬰ«e¦C¸¢ÀùÂಾ¡A«h¥i¥HÀu¥ý¦Ò¼{²üº¸»XªvÀø¡C
 
(D) 4. ¤â³N«á»²§U©Ê¤Æ¾ÇªvÀø¤w³QÃÒ¹ê¦b³\¦hÀù¯g¤¤¥i¦³®Ä§ïµ½¯f±w¦s¬¡²v¡C¥H¤U¦óªÌ¨Ò¥~?
A.¨ÅÀù¨Ö¦P°¼µÅ¤U²O¤Úµ²Âಾ¡C
B.§Z±_Àù¨Ö¸¡µÄ¤ºÂಾ¡C
C.¤j¸zÀù¨Ö§½³¡²O¤Úµ²Âಾ¡C
D.­GÀù¨Ö§½³¡²O¤Úµ²Âಾ¡C
E.¥Í´Þ²Ó­M½F¨Ö >5¤½¤À¤§«á¸¡µÄ²O¤Úµ²Âಾ¡]stage¢ºC¡^¡C
 
(D) 5. ¦³Ãö¡u°ª¾¯¶q¤Æ¾ÇªvÀø¡v¦bÀù¯g±wªÌªº¨Ï¥Î¡A¤U¦C±Ô­z¦óªÌ¿ù»~¡H
A.¨Ï¥Î¡u¦ÛÅé¡]autologous¡^°©Åè²¾´Ó¡v»P¡u²§Åé¡]allogeneic¡^°©Åè²¾´Ó¡v¬Û¸û¡A¯f±w¦b±µ¨ü²¾´Ó«á¥Õ¦å²y¤Î¦å¤pªO«ì´_ªº³t«×³£¤ñ¸û§Ö¡C
B.´c©Ê²O¤Ú½F´_µo®É ¡A­Y¤´µM¹ï¶Ç²Î¤Æ¾ÇªvÀø¦³¤ÏÀ³¡]chemosensitive relapse¡^¡A«h¨Ï¥Î°ª¾¯¶q¤Æ¾ÇªvÀø¦X¨Ö³y¦å²Ó­M²¾´Ó¥i¥H´£°ªªø´Á¦s¬¡¤§¾÷·|¡C
C.ºC©Ê°©Åè©Ê¥Õ¦å¯f¡]chronic myelogenous leukemia¡^¦bºC©Ê´Á¡]chronic phase¡^®É¡A¦pªG¦³¦X¾Aªº°©Å讽Ãت̡AÀ³ºÉ¶q¦b¶EÂ_«á¤@¦~¤º±µ¨ü°©Åè²¾´Ó¡C
D.¨ÅÀù¦X¨Ö¨xŦÂಾ¡A¨Ï¥Î¡u°ª¾¯¶q¤Æ¾ÇªvÀø¦X¨Ö³y¦å¥À²Ó­M²¾´Ó¡v¸û¶Ç²Î¤Æ¾ÇªvÀø¦³¸û°ª¤§ªv¡²v¡C
E.´¿¸g±µ¨ü¡u°ª¾¯¶q¤Æ¾ÇªvÀø¦X¨Ö³y¦å¥À²Ó­M²¾´Ó¡vªº¯f±w¡A¥H«á²£¥Í¦¸µo©Ê´c©Ê¸~½F¡]second malignancy¡^ªº¾÷·|¸û¤@¯ë¤H¬°°ª¡C
 
(B) 6. ¤â³N¤Á°£¦Ü¤µ¤´µM¬O¤j¦h¼ÆÀù¯g³Ì¥D­nªºªvÀø¤è¦¡¡A¤U¦C¦óªÌ°£¥~¡H
A.Pancreatic cancer
B.Small cell lung cancer
C.Cholangiocarcinoma
D.Malignant fibrous histiocytoma
E.Gastric cancer
 
(E) 7. 40·³¨k©Ê¡A¦]¬°³sÄò¤T­Ó¤ë¤W¸¡µh«e¨Ó´N¶E¡C²z¾ÇÀˬdµL¯S§O²§±`¡C¸¡³¡¶W­µªi¤Î¹q¸£Â_¼hÀˬd§¡µo²{¥D°Ê¯ß®Ç¦h³B²O¤Úµ²¸~¤j¡]para-aortic lymphadenopathy¡^¡C¤U¦C±Ô­z¦óªÌ¿ù»~¡H
A.²Õ´¤Á¤ù¥HÀò±o¯f²z¶EÂ_¬O¥²­nªºÀˬd¡C
B.¸~½F«ü¼Ð¦p CEA¡]carcinoembryonic antigen¡^¡A£\-fetoprotein¥iÀ°§UŲ§O¶EÂ_¡C
C.¸~½F¬V¦âÅéÀˬd¡]cytogenetic analysis¡^¥iÀ°§UŲ§O¶EÂ_¡C
D.­Y½T©w¬°´c©Ê¸~½F,¥B²Õ´§K¬Ì¬V¦â common leukocyte antigen ¬°¶§©Ê¡A¥i¶EÂ_¬°´c©Ê²O¤Ú½F¡C
E.­Y¯f²z¶EÂ_¬° poorly differentiated carcinoma¡A¥B£]-HCG¡] human chorionic gonadotropin¡^¤W¤É¡A«h¤â³N¤Á°£¬°­º¿ïªvÀø¤è¦¡¡C
 
(A) 8. Ãö©ó´c©Ê²O¤Ú½Fªº±Ô­z¡A¤U¦C¦óªÌ¿ù»~¡H
A.§C´c©Ê«×²O¤Ú½F¡]low grade lymphoma¡^¤@¯ë¦Ó¨¥§¡¥i¥H¤Æ¾ÇªvÀøªv¡¡C
B.Performance status, LDH¡]lactate dehydrogenase¡^level, extranodal involvement §¡¬° diffuse large cell lymphoma ¤§­«­n¹w«á¦]¤l¡C
C.Lymphoblastic lymphoma ¦]©ö²£¥Í¤¤¼Ï¯«¸g¨t²Î«I¥Ç¡A¦]¦¹¤j³¡¤À±M®a»{¬°ªvÀø¹Lµ{¤¤À³¥[¤J CNS prophylaxis¡C
D.¡u¦¨¤HT²Ó­M²O¤Ú½F/¥Õ¦å¯f¡v¡]adult T cell lymphoma/leukemia¡^»P retrovirus ·P¬V¦³Ãö¡C
E.Burkitt's lymphoma ¯f±w¦b±µ¨ü¤Æ¾ÇªvÀø®É©ö¨Öµo¡u¸~½F·»¸Ñ¯g­Ô¸s¡v¡]tumor lysis syndrome¡^¡A¥²¶·¨Ï¥Î hydration, urine alkalization¤Îallopurinol¹w¨¾¡C
 
(D) 9. Ãö©ó¨ÅÀùªº²üº¸»XªvÀø¡A¥H¤U±Ô­z¦óªÌ¥¿½T¡H 1. °±¸g«á¨ÅÀù¯f±w¸g¤â³NªvÀø«á¡A¦pªG¦P°¼µÅ¤U²O¤Úµ²Âಾ¡A¥B¸~½F¤§»Û¿E¯À±µ¨üÅé¡]estrogen receptor¡^¬°¶§©Ê¡A«hÀ³±µ¨ü»²§U©Ê tamoxifen ªvÀø¡C 2. ¨ÅÀù¯f±w¤â³NªvÀø«á±µ¨ü»²§U©Ê tamoxifen ªvÀøªÌ¡A«h¨ä¥t¤@°¼¨Å©Ð²£¥Í¨ÅÀùªº¾÷·|¤]·|­°§C¡C 3. ªø´Á¨Ï¥Î tamoxifen ªº¤k©Ê¥H«á²£¥Í¤l®c¤º½¤Àù¡]endometrial carinoma¡^ªº¾÷·|¸û¤@¯ë¤k©Ê¬°°ª¡C 4. ¨ÅÀù¦X¨Ö¦h³B¥Ö½§¤ÎÀV³¡²O¤Úµ²Âಾ¡A­Y¸~½F¤§»Û¿E¯À±µ¨üÅé¡]estrogen receptor¡^¤Î§U¥¥¿E¯À±µ¨üÅé¡]progesterone receptor¡^§¡¬°¶§©Ê,«h¥iÀu¥ý¦Ò¼{¨Ï¥Î²üº¸»XªvÀø¡C 5. Âಾ©Ê¨ÅÀù¯f±w¸g²Ä¤@½u²üº¸»XªvÀø±o¨ì½w¸Ñ¡]remission¡^ ¡A¥H«á¸~½F¦A«×´c¤Æ®É¡A¹ï©ó¨ä¥L²üº¸»XÃĪ«ªvÀø³q±`µL®Ä¡C
A.1,3,4
B.1,2,4
C.1,2,4,5
D.1,2,3,4
E.1,2,3,4,5
 
(D) 10. Ãö©óÁû²É©Ê¥Õ¦å²y¥Íªø¯À¡]granulocyte-colony stimulating factor, G-CSF¡^¦bÀù¯g¯f±wªº¨Ï¥Î¡A¤U¦C±Ô­z¦óªÌ¥¿½T¡H 1. ¥i¥H´î¤Ö¦]¤Æ¾ÇªvÀø²£¥Í¥Õ¦å²y­°§C¡]granulocytopenia¡^¤§¾÷²v¤ÎÄY­«µ{«× 2. ¥i¥H´î§C¯f±w¦]¥Õ¦å²y­°§C²£¥Í¤§·P¬Vªº¾÷²v 3. ¥i¥Î©ó°©Åè²¾´Ó«á¥H¥[³t¥Õ¦å²y¼Æ«ì´_ 4. ¥i¥Î©ó¦¬¶°©PÃä¦å³y¦å¥À²Ó­M¡]peripheral blood progenitor cell harvest¡^¥H«K¶i¦æ°ª¾¯¶q¤Æ¾ÇªvÀø 5. ¥i¦³®Ä©µªøÀù¯g¯f±w¤§¦s¬¡²v
A.1,3,5
B.1,2,4
C.1,4,5
D.1,2,3,4
E.1,2,3,5
 


< ¤K¤Q¤C¦~¸ÕÃD¥Ø¿ý >